Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23628841 | 1.00 | TSHR (0.38) | TSHRTRPA1CYP2D6ALDH1A1HTT | |
| SCHEMBL4073531 | 0.81 | LMNA (0.39) | ALDH1A1HTTLMNAUSP2HPGD | |
| SCHEMBL6888751 | 0.80 | TSHR (0.38) | TSHRTRPA1ALDH1A1HTTL3MBTL1 | |
| SCHEMBL23628847 | 0.77 | LMNA (0.36) | ALDH1A1HTTLMNAUSP2HPGD | |
| SCHEMBL2494300 | 0.77 | KIF11 (0.37) | — | |
| SCHEMBL2490903 | 0.76 | ACP3 (0.41) | TSHRMAPK1 | |
| SCHEMBL28201035 | 0.72 | CYP2D6 (0.39) | TSHRCYP2D6ALDH1A1L3MBTL1SRC | |
| Bromide SCHEMBL14157204 | 0.72 | SMN1; SMN2 (0.38) | TSHRALDH1A1KMT2ALMNAUSP2 | |
| SCHEMBL2936982 | 0.68 | TRPA1 (0.41) | TSHRTRPA1CYP2D6ALDH1A1L3MBTL1 | |
| SCHEMBL19646056 | 0.68 | TSHR (0.52) | TSHRTRPA1CYP2D6ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771177-A4 | PROCESSES AND INTERMEDIATES USEFUL FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1761268-A4 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1771177-A2 | PROCESSES AND INTERMEDIATES USEFUL FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1768983-A2 | FUSED HETEROCYCLIC KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1761268-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-03-14 | — | — | EP | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| EP-1635800-A2 | CARBONYL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2006004884-A2 | PROCESSES AND INTERMEDIATES USEFUL FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004636-A2 | FUSED HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004833-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2004110418-A2 | CARBONYL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| US-4418070-A | 5-PHENYL-THIAZOLES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1983-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | TSHR 2615/4885TRPA1 3765/4885CYP2D6 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.